NICE approves innovative treatment for moderate to severe heart failure

Doctors have a new treatment option for patients whose heart failure is not controlled by angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, after the National Institute for Health and Care Excellence (NICE) approved sacubitril valsartan (Entresto).1